Development and characterization of solid lipid dispersion as delivery system for hydrophilic antihypertensive drug atenolol

International Journal of Drug Delivery

Volumn 4, Issue 2, 2012, Pages

  El Leithy, Eman Sadder ^a   Nasr, Mohamed ^a   El Moneum, Raghda Abd ^a  

^a HELWAN UNIVERSITY   (Egypt)

Author keywords

Atenolol; Lipophilic excipients; Permeation; Solid dispersion; Sustained release; Water soluble drug

Indexed keywords

ATENOLOL; DRUG CARRIER; EXCIPIENT; GLYCEROL STEARATE; LAURIC ACID; MYRISTIC ACID; PALMITIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SATURATED FATTY ACID; SORBITAN STEARATE; SURFACTANT; TRIACYLGLYCEROL; TRISTEARIN; DRUG ADDITIVE; PALMETIC ACID; PHOSPHOTIDYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; COEVAPORATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; ENCAPSULATION; EVAPORATION; HYDROPHILICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; NONHUMAN; RABBIT; SOLID LIPID DISPERSION; DRUG PENETRATION; DRUG PURITY; DRUG SYNTHESIS; PROCESS DEVELOPMENT; SUSTAINED DRUG RELEASE;

EID: 84877327091     PISSN: None     EISSN: 09754415     Source Type: Journal    
DOI: 10.5138/ijdd.v4i2.625     Document Type: Article

References (24)

1. Koga K, Takarada N, Takada K. Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability Compound. Eur. J. Pharm. Biopharm. 2010, 74 (2), 223-32.
2. Wang S, Sun M, Ping Q. Enhancing effect of labrafac lipophile WL 1349 on oral bioavailability of hydroxysafflor yellow A in rats. Int. J. Pharm. 2008 Jun 24,358(1-2), 198-204.
3. Takada K. Oral delivery of hematopoietic factors: progress with gastrointestinal mucoadhesive patches, microdevices, and other microfabrication technologies. Am. J. Drug Del. 2006, 4, 65-77.
4. Deshmukh DD, Ravis WR, Betageri GV. Improved delivery of cromolyn from oral proliposomal beads. Int. J. Pharm. 2008 24,358(1-2), 128-164.
5. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert RO, Martin F, Müller-Goymann C. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res. 2010, 27(8), 1469-1555.
6. Ali O, Obaid R, Saify ZS, Ahmed SW. Biopharmaceutical evaluation of oral tablet Atenolol (100 and 50 mg) on local population. Pak. J. Pharm. Sci. 2005, 18(1), 25-32.
7. Milind P, Wagh J, Patel S. Biopharmaceutical Classification System: Scientific Basis for Bilayer Extensions Int. J. Pharm. Pharm. Sc. 2010, 2(1), 12-19.
8. Jug M, Bećirević-Laćan M, Bengez S. Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol. Drug. Dev. Ind. Pharm. 2009 35(7), 796-807.
9. Wu F, Cheni P, Lee YJ, Long RR. Comparative Pharmacokinetics of Two Atenolol Products. Journal of Food and Drug Analysis.2003, 4-7.
10. Sastry SV, Reddy IK, Khan MA. Atenolol gastrointestinal therapeutic system: Optimization of formulation variables using response surface methodology. J. Control. Release. 1997, 45,121-130.
11. Singh B, Kaur S, Chakkal AN. Formulation and Optimization of Controlled Release Mucoadhesive Tablets of Atenolol Using Response Surface Methodology. AAPS. Pharm. Sci. Tech. 2006, 7(1), 3.
12. Vaithiyalingam SR, Sastry SV, Dehon RH, Reddy IK, Khan MA. Long-term stability characterization of a controlled release gastrointestinal therapeutic system coated with cellulose acetate pseudolatex. Pharmazie. 2001, 56, 66-69.
13. Kim J, Shin SC. Controlled release of atenolol from the ethylene-vinyl acetate matrix. Int. J. Pharm. 2004,273, 23-27.
14. Jug M, Bećirević-Laćan M, Bengez S. Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol. Drug Dev. Ind. Pharm. 2009, 35(7), 796-807.
15. Kulkarni A, Bhatia M. Development and Evaluation of Regioselective Bilayer Floating Tablets of Atenolol and Lovastatin for Biphasic Release Profile. Iranian J. Pharma. Res. 2009, 8 (1), 15-25.
16. Srivastava AK, Wadhwa S, Ridhurkar D, Mishra B. Oral Sustained Delivery of Atenolol from floating Matrix Tablets-Formulation and in vitro Evaluation. Drug. Dev. Ind. Pharm. 2005, 31(4-5), 367-74.
17. Nokhodchi A, Talari R, Valizadeh H, Jalali MB. An investigation on the solid dispersions of chlordiazepoxide. Int. J. Bio. 2007, 3,211-217.
18. Hammady T, El-Gindy A, Lejmi E, Dhanikula RS, Moreau P, Hildgen P. Characteristics and properties of nanospheres co-loaded with lipophilic and hydrophilic drug models. Int. J. Pharm. 2009, 18,369(1-2), 185-95.
19. Smith PL. Methods for evaluating intestinal permeability and metabolism in-vitro. Pharm. Biotechnol. 1996, 8, 13-34.
20. Rafael NP, Bruno RV, Ariane PC, Talize F, Fabio SM, Marcos AS. Thermo analytical Study of Atenolol and Commercial Tablets. Lat. Am. J. Pharm. 2007, 26, (3), 382-388.
21. Sharma P, Varma MV, Chawla HP, Panchagnula R. Relationship between lipophilicity of BCS class III and IV drugs and the functional activity of peroral absorption enhancers. Farmaco. 2005, 60(11-12), 870-873.
22. Wang T, Wang N, Hao A, He X, Li T, Deng Y. Lyophilization of water-in-oil emulsions to prepare phospholipid-based anhydrous reverse micelles for oral peptide delivery. Eur. J. Pharm. Sci. 2010, 18, 39(5), 373-382.
23. Kawaguchi E, Shimokawa K, Ishii F. Physicochemical properties of structured phosphotidylcholine in drug carrier lipid emulsions for drug delivery systems. Colloids Surf. B. Biointerfaces. 2008, 62(1), 130-135.
24. Robhash KS, Keon WK, Hoo-Kyun C. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J. Pharm. Sci. 2009, 37, 508-513.